Ozempic (semaglutide) is FDA-approved for type 2 diabetes. This article covers mechanism, evidence base, FDA labeling, safety, and the upstream genetic variables — including TCF7L2, GLP1R, and FTO — that shape every type 2 diabetes decision.

Tirzepatide and semaglutide are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Semaglutide and tirzepatide are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Retatrutide and tirzepatide are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Trulicity (dulaglutide) is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

Zepbound (tirzepatide) was FDA-approved in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity. This article covers SURMOUNT-OSA trial outcomes, mechanism, safety, and the GLP-1 pathway genetics.

Semaglutide (semaglutide, marketed under multiple brand names (Ozempic, Wegovy, Rybelsus); also available through licensed compounding pharmacy pathways) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Retatrutide (retatrutide, Eli Lilly) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Mounjaro (tirzepatide) is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including GIPR, GLP1R, and FTO — that sit upstream of any decision.

Ozempic (semaglutide) is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

Wegovy (semaglutide) is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

Trulicity (dulaglutide, Eli Lilly) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

GLP-1 — glucagon-like peptide-1 — is an incretin hormone. The GLP-1 receptor agonist drug class mimics it pharmacologically. This article covers GLP-1 hormone biology, how the drug class works, what's FDA-approved as of April 2026, and the GLP-1 pathway genetics including GLP1R, FTO, and MC4R.

Semaglutide is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

GLP-1 receptor agonist medications (GLP-1 receptor agonists) is FDA-approved as a GLP-1 pathway compound. This article covers mechanism, evidence base, FDA indications, limitations, and the GLP-1 pathway genetics — including FTO, GLP1R, and MC4R — that sit upstream of any decision.

Rybelsus (oral semaglutide, Novo Nordisk) is a GLP-1 receptor agonist with a well-characterized safety profile. This article covers common side effects, serious warnings, the boxed-warning context, and when to call a provider — plus the genetic variables that shape baseline GLP-1 biology.

Zepbound (tirzepatide) and Mounjaro (tirzepatide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Mounjaro (tirzepatide) and Zepbound (tirzepatide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Zepbound (tirzepatide) and Ozempic (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Semaglutide oral availability, FDA-approved oral GLP-1 options as of April 2026, how oral GLP-1 absorption works, cost, and the PlexusDx Semaglutide Oral and Tirzepatide Oral protocols inside the Weight Management Protocols collection.

Ozempic (semaglutide) and Mounjaro (tirzepatide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Mounjaro (tirzepatide) and Ozempic (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Zepbound (tirzepatide) and Wegovy (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Wegovy (semaglutide) and Zepbound (tirzepatide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including GIPR, GLP1R, and FTO — that apply regardless of which compound is prescribed.

Wegovy (semaglutide) and Ozempic (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including FTO, GLP1R, and MC4R — that apply regardless of which compound is prescribed.

GLP-1 — glucagon-like peptide-1 — is an incretin hormone. The GLP-1 receptor agonist drug class mimics it pharmacologically. This article covers GLP-1 hormone biology, how the drug class works, what's FDA-approved as of April 2026, and the GLP-1 pathway genetics including GLP1R, FTO, and MC4R.

Ozempic (semaglutide) and Wegovy (semaglutide) are compared across mechanism, FDA-approved indications, evidence base, side effects, cost, and the pathway-level genetic variants — including FTO, GLP1R, and MC4R — that apply regardless of which compound is prescribed.

Semaglutide oral availability, FDA-approved oral GLP-1 options as of April 2026, how oral GLP-1 absorption works, cost, and the PlexusDx Semaglutide Oral and Tirzepatide Oral protocols inside the Weight Management Protocols collection.

Microdose GLP-1 protocols use lower-than-standard doses of GLP-1 receptor agonists titrated by a clinician for better tolerability. This article covers what microdose means, the rationale, and the PlexusDx Microdose GLP-1 protocol inside the Weight Management Protocols collection.

Ozempic Vulva explained — what is being described, why it can happen, what the published trial evidence shows, and the GLP-1 pathway genetic context. Treated with clinical dignity. Individual results vary.